Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aurinia Pharmaceuticals Inc. (AUPH) Healthcare & Pipeline Overview

Aurinia Pharmaceuticals Inc. is a leading biopharmaceutical company dedicated to addressing unmet medical needs through innovative therapies, notably its flagship product LUPKYNIS, which targets lupus nephritis and showcases strong market potential.

What Is the Investment Thesis for AUPH?

With a market capitalization of $2.07B and a P/E ratio of 6.83, the company is positioned favorably compared to industry peers. The ongoing collaboration with Otsuka Pharmaceutical Co., Ltd. is expected to enhance market penetration and revenue growth, particularly as the global lupus nephritis market is projected to grow significantly in the coming years. Additionally, Aurinia's impressive profit margin of 100% indicates strong operational efficiency. Key risks include potential regulatory hurdles and competition from alternative therapies, which could impact market share and revenue growth. However, the company's focus on innovation and strategic partnerships provides a solid foundation for future growth.

Based on FMP financials and quantitative analysis

AUPH Key Highlights

Market Cap of $2.07B indicates strong market presence in the biotechnology sector.

• P/E ratio of 6.83 suggests attractive valuation compared to industry peers.
• Profit margin of 100% reflects exceptional operational efficiency and profitability.
• Gross margin of 89.7% exceeds industry averages, highlighting strong pricing power.
• Beta of 1.59 indicates higher volatility compared to the market, suggesting potential for significant price movements.

Who Are AUPH's Competitors?

AUPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AUPH's Key Strengths?

Strong product offering with LUPKYNIS addressing a critical need.

• High profit and gross margins demonstrating financial health.
• Strategic partnership with Otsuka enhances market access.

What Are AUPH's Weaknesses?

Limited product portfolio focused primarily on lupus nephritis.

• Dependence on a single product for revenue generation.
• Relatively small workforce may limit operational scalability.

What Could Drive AUPH Stock Higher?

Expansion of LUPKYNIS into new international markets expected to drive revenue growth.

• Collaboration with Otsuka Pharmaceutical Co., Ltd. enhancing distribution capabilities.
• Potential new indications for LUPKYNIS could diversify revenue streams.

What Are the Key Risks for AUPH?

Regulatory hurdles could delay product approvals and market entry.

• Competition from other biopharmaceutical companies in the autoimmune space.
• Market volatility may impact stock performance and investor sentiment.

What Are the Growth Opportunities for AUPH?

• Growth opportunity 1: The global lupus nephritis market is projected to reach $5 billion by 2027, driven by increasing prevalence and awareness. Aurinia's LUPKYNIS, being one of the few approved treatments, positions the company to capture a significant share of this expanding market over the next five years.
• Growth opportunity 2: Aurinia's collaboration with Otsuka Pharmaceutical Co., Ltd. enhances its distribution capabilities, allowing for broader market access and increased sales potential. This partnership is expected to accelerate market penetration and revenue growth, particularly in regions with high unmet needs.
• Growth opportunity 3: The company is exploring additional indications for LUPKYNIS beyond lupus nephritis, which could diversify its product portfolio and open new revenue streams. If successful, this could significantly enhance the company’s market position and financial performance.
• Growth opportunity 4: Continued investment in R&D could lead to the development of new therapies targeting other autoimmune diseases. With a focus on unmet medical needs, Aurinia has the potential to expand its therapeutic offerings and strengthen its market presence.
• Growth opportunity 5: Increasing collaborations and partnerships within the biotechnology sector can enhance Aurinia's research capabilities and accelerate the development of new products. This strategy could position the company for sustained growth and innovation in the competitive landscape.

What Are AUPH's Competitive Advantages?

• Strong intellectual property protection for LUPKYNIS.
• Established partnerships with major pharmaceutical companies like Otsuka.
• Focused expertise in lupus nephritis, providing a competitive advantage.
• High profit margins indicating operational efficiency.
• Limited competition in the specific treatment area of lupus nephritis.

What Does AUPH Do?

Founded in 2013 and headquartered in Victoria, Canada, Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that specializes in developing and commercializing therapies for diseases with significant unmet medical needs. The company has made substantial strides in the biotechnology sector, particularly with its primary product, LUPKYNIS (voclosporin), which is designed for the treatment of adult patients suffering from active lupus nephritis. This condition, characterized by inflammation of the kidneys due to lupus, presents a significant challenge in patient management and has limited treatment options. Aurinia's commitment to addressing this gap in the market has positioned it as a key player in the healthcare landscape. The company has also established a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., enhancing its commercial capabilities and market reach. With a workforce of approximately 130 employees, Aurinia is focused on expanding its product offerings and improving patient outcomes through innovative therapies. The company's strategic focus on unmet medical needs, combined with its strong financial metrics, including a profit margin of 100% and a gross margin of 89.7%, underscores its potential for growth and sustainability in the competitive biopharmaceutical market.

What Products and Services Does AUPH Offer?

• Develops and commercializes therapies for diseases with unmet medical needs.
• Offers LUPKYNIS, a treatment for adult patients with active lupus nephritis.
• Engages in collaborations with other pharmaceutical companies to enhance market reach.
• Focuses on innovative solutions in the biopharmaceutical space.
• Operates primarily in the United States and internationally.
• Aims to improve patient outcomes through targeted therapies.

How Does AUPH Make Money?

• Generates revenue primarily through the sale of LUPKYNIS.
• Engages in strategic partnerships to enhance distribution and market access.
• Invests in R&D to develop new therapies and expand product offerings.
• Utilizes licensing agreements to monetize its innovations.
• Focuses on addressing unmet medical needs to drive demand for its products.

What Industry Does AUPH Operate In?

The biotechnology industry is experiencing robust growth, driven by advancements in medical research and increasing demand for innovative therapies. The global lupus nephritis market is anticipated to expand significantly, fueled by rising awareness and diagnosis rates. Aurinia Pharmaceuticals Inc. is well-positioned within this landscape, leveraging its specialized focus on lupus nephritis to capture market share. The competitive landscape includes several established players, but Aurinia's unique product offering and strategic partnerships provide a competitive edge.

Who Are AUPH's Key Customers?

• Healthcare providers and hospitals treating lupus nephritis patients.
• Pharmaceutical distributors and wholesalers.
• Patients seeking effective treatments for lupus nephritis.
• Insurance companies covering treatments for autoimmune diseases.
• Research institutions collaborating on clinical trials.

Company Profile

Aurinia Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Edmonton, CA. The company is led by CEO Kevin C. Tang. AUPH has traded publicly since 2014.

Return on equity for Aurinia Pharmaceuticals Inc. stands at 64.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 41.2%, showing how much profit it generates from its asset base. AUPH trades at a trailing price-to-earnings ratio of 6.83, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 8.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 14.4%, the inverse of the P/E and a quick read on earnings relative to price.

AUPH Valuation & Market Position

With a $2.07B market cap, Aurinia Pharmaceuticals Inc. sits in the mid-cap segment of the market. Analyst price targets span from $16.00 to $16.00, with a consensus of $16.00. At the current price of $16.11, that implies roughly 1% downside from the consensus target. Relative to its peer group, AUPH's quantitative score of 90/100 is roughly in line with the peer average of 83/100.

Quarterly Financial Performance: Aurinia Pharmaceuticals Inc.

Revenue for Aurinia Pharmaceuticals Inc. came in at $83.2M during Jun 2026, a 7.1% improvement versus the preceding quarter. The company recorded net income of $37.4M, with diluted EPS of $0.28. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, AUPH averaged $0.57 in diluted EPS.

Aurinia Pharmaceuticals Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.81 places it in the safe zone, indicating low near-term bankruptcy risk.

Aurinia Pharmaceuticals Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 68.8% above estimates on average.

Wall Street analysts project Aurinia Pharmaceuticals Inc. revenue of about $330.3M for fiscal 2026, with EPS near $0.94. The estimate reflects 5 contributing analysts.

Over the past six months, Aurinia Pharmaceuticals Inc. insiders filed 16 SEC Form 4 transactions — 1 sales and 15 purchases. On net that is roughly 1.4M shares acquired (about $15.9M) — insiders putting money in tends to read as conviction.

AUPH Financials

AUPH Latest News

AUPH Analyst Consensus

AUPH MoonshotScore

AUPH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources